Aubrey Rankin - Director, Revance Therapeutics, Inc
As of March 17, 2022
Aubrey Rankin Net Worth
- Net worth is estimated to be at least $17.24M
- Owns at least 417,074 units of Revance Therapeutics, Inc stock
- Sold an estimated value of $8.82M in the last 2 years at Revance Therapeutics, Inc
Aubrey Rankin Trading
- Largest purchase of shares was 30,000 units , worth over $432.88K on December 6, 2021
- Largest sale of shares was 55,382 units , worth over $1.65M on July 28, 2021
- In total has made about 14 transactions over 2 years
- Usually trades in July, with the busiest year in 2021
Aubrey Rankin
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
Aubrey Rankin Mailing Address
- Mailing address is C/o Revance Therapeutics, Inc 7555 Gateway Blvd Newark CA 94560 CA
Revance Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Mark J. Foley | 2020 | $650,000 | $ | $7,794,350 | $ | $328,331 | $8,255 | $8,780,936 |
| Mark J. Foley | 2019 | $189,764 | $150,000 | $11,728,370 | $5,112,573 | $ | $9,723 | $17,190,430 |
| Tobin C. Schilke | 2020 | $421,375 | $ | $1,131,345 | $1,273,662 | $143,186 | $11,531 | $2,981,099 |
| Tobin C. Schilke | 2019 | $407,126 | $25,000 | $86,150 | $299,781 | $178,123 | $11,078 | $1,007,258 |
| Tobin C. Schilke | 2018 | $64,644 | $25,000 | $449,280 | $1,434,350 | $ | $233 | $1,973,507 |
| Abhay Joshi, Ph.D. | 2020 | $514,608 | $ | $1,405,850 | $1,913,759 | $213,726 | $11,731 | $4,059,674 |
| Abhay Joshi, Ph.D. | 2019 | $485,479 | $ | $271,373 | $939,314 | $204,211 | $9,520 | $1,909,897 |
| Abhay Joshi, Ph.D. | 2018 | $469,062 | $ | $342,513 | $1,192,465 | $232,186 | $9,210 | $2,245,436 |
| Dustin Sjuts | 2020 | $415,000 | $ | $1,294,250 | $1,306,320 | $141,020 | $66,242 | $3,222,832 |
| Dustin Sjuts | 2019 | $378,333 | $50,000 | $43,075 | $99,927 | $183,902 | $45,786 | $801,023 |
| Dwight Moxie | 2020 | $370,104 | $125,000 | $1,309,383 | $2,579,240 | $125,426 | $10,356 | $4,519,508 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000089/rvncfy20proxystatementdef1.htm
Revance Therapeutics, Inc Insider Trading
- The most recent transaction was 6,400 units bought on December 15, 2021 by Angus Russell worth over $100.74K
- In the last 7 years, insiders at Revance Therapeutics, Inc sold an estimated value of $29.8M and bought an estimated value of $8.6M
- The most active traders are Daniel Browne, CEO and President, Curtis Ruegg, EVP, and Lauren Silvernail, CFO & CBO
- Insider trading is most common in May, with the busiest year in 2021
Revance Therapeutics, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||